Alpha Teknova Q2 revenue beats estimates, raises revenue 2026 outlook
TKNO•Drivers of the quarter
Alpha Teknova said revenue growth was driven by increased demand across nearly all end markets.
The company also attributed results to investments in its commercial organization, facilities and manufacturing systems.
It launched Build-Tek, an AI-powered custom order configurator, in the quarter to speed product development.
Guidance raised for 2026
The company raised its 2026 revenue guidance to $45 million to $47 million.
Alpha Teknova now expects 2026 free cash outflow of less than $8 million. The company said it sees long-term growth as the biotech market continues to recover.
Q2 revenue beats estimates
US reagents producer Alpha Teknova said second-quarter revenue rose 18% year over year, beating analyst expectations.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $12.19 mln | $10.97 mln (6 Analysts) |
| Q2 Loss Per Share | $0.06 | ||
| Q2 Net Loss | $3.17 mln | ||
| Q2 Gross Profit | $4.89 mln |
Analyst coverage and valuation
The current average analyst rating on the shares is "buy," with 5 "strong buy" or "buy" ratings, 2 "hold" ratings and no "sell" or "strong sell" ratings.
The average consensus recommendation for the medical equipment, supplies and distribution peer group is "buy."
